EUCTR2014-000529-19-RO进行中（未招募）1 期
A 12 week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects with COPD
GlaxoSmithKline R&D0 个研究点目标入组 627 人开始时间: 2014年5月30日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 627
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Subjects eligible for enrolment in the study must meet all of the following criteria:
- •1. Type of subject: Outpatient.
- •2. Informed Consent: A signed and dated written informed consent prior to study participation.
- •3. Age: 40 years of age or older at Visit 1.
- •4. Gender: Male and female subjects are eligible to participate in the study.
- •A female is eligible to enter and participate in the study if she is of:
- •Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being
- •amenorrhoeic for greater than 1 year with an appropriate clinical profile (e.g. age appropriate, > 45 years, in the absence of hormone replacement therapy.
- •Child bearing potential provided the subject has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e. in accordance with the approved product label, if appropriate, and the instructions of the physician for the duration of the study –
- •screening to follow-up contact):
- •-Abstinence
- •-Oral contraceptive, either combined or progestogen alone
- •-Injectable progestogen
- •-Implants of levonorgestrel
- •-Estrogenic vaginal ring
- •-Percutaneous contraceptive patches
- •-Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP effectiveness criteria as stated in the product label
- •-Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, documented” refers to the outcome of the
- •investigator's/designee’s medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject’s medical records.
- •-Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)
- •5. Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society [Celli, 2004].
- •6. Smoking History: Current or former cigarette smokers with a history of cigarette smoking of >or= 10 pack-years [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g. 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years both equal 10 pack-years)]. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Pipe and/or cigar use cannot be used to calculate pack-year history.
- •7. Severity of Disease: A pre and post-albuterol/salbutamol FEV1/FVC ratio of <0.70 and a post-albuterol/salbutamol FEV1 of <or=70% of predicted normal values calculated using NHANES III reference equations at Visit 1 [Hankinson, 1999; H
排除标准
- •Subjects meeting any of the following criteria must not be enrolled in the study:
- •1. Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
- •2. Asthma: A current diagnosis of asthma.
- •3. Other Respiratory Disorders: Known alpha-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer are absolute exclusionary conditions. A subject who, in the opinion of the investigator, has any other significant respiratory conditions in addition to COPD should be excluded. Examples may include clinically significant bronchiectasis, pulmonary hypertension,
- •sarcoidosis, or interstitial lung disease.
- •4. Other Diseases/Abnormalities: Any subject who is considered unlikely to survive the duration of the study period or has any rapidly progressing disease or immediate life-threatening illness (e.g. cancer). In addition, any subject who has any condition
- •(e.g. neurological condition) that is likely to affect respiratory function should not be included in the study.
- •5. Severe Hepatic Impairment: Patients with severe hepatic impairment (Child-Pugh class C) should be excluded unless, in the opinion of the investigator, the benefit is likely to outweigh the risk.
- •6. Unstable or life threatening cardiac disease: Umeclidinium/vilanterol should be used with caution in subjects with severe cardiovascular disease. In the opinion of the investigator, use should only be considered if the benefit is likely to outweigh the risk in conditions such as:
- •-Myocardial infarction or unstable angina in the last 6 months
- •-Unstable or life threatening cardiac arrhythmia requiring intervention in the last 3 months
- •-NYHA Class IV heart failure
- •7. Contraindications: Any history of allergy or hypersensitivity to any
- •anticholinergic/muscarinic receptor antagonist, beta2-agonist, sympathomimetic, lactose/milk protein or magnesium stearate.
- •8. Antimuscarinic effects: Subjects with medical conditions such as narrow-angle glaucoma, urinary retention, prostatic hypertrophy, or bladder neck obstruction should only be included if, in the opinion of the study physician, the benefit outweighs the risk.
- •9. Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.
- •10. Lung Resection: Lung volume reduction surgery within the 12 months prior to Visit 1.
- •11. 12-Lead ECG: Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. The Investigator will determine the clinical significance of each abnormal ECG finding in relation to the subject’s medical history and exclude subjects who would be at undue risk by participating in the trial. Subjects with the following abnormalities are excluded from participation in the study:
- •-Atrial fibrillation with rapid ventricular rate >120 bpm
- •-Sustained or nonsustained ventricular tachycardia
- •-Second degree heart block Mobitz type II and third degree heart block (unless pacemaker or defibrillator had been inserted)
- •12. Medication Prior to Spirometry: Unable to withhold albuterol/salbutamol for the 4 hou
研究者
相似试验
进行中（未招募）
不适用
A 12 week study to compare the effect of two medicines in one inhaler compared to placebo in COPD patientsSubjects with COPDMedDRA version: 17.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-000529-19-BGGlaxoSmithKline R&D496
进行中（未招募）
不适用
A 12 week study to compare the effect of two medicines in one inhaler compared to placebo in COPD patientsEUCTR2014-000529-19-HUGlaxoSmithKline R&D496
进行中（未招募）
不适用
A 12 week study to compare the effect of two medicines in one inhaler compared to placebo in COPD patientsEUCTR2014-000529-19-DEGlaxoSmithKline R&D496
招募中
不适用
A 12 week, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of PS01 on Reducing Body FatKCT0006619ovaKmed120
已完成
不适用
A 12 week, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of Lactobacillus plantarum LRCC5282 on Reducing Body FatKCT0008119otte Chilsung Beverage120